Device to Treat Refractory Angina Featured in Live Case at TCT
September 28, 2010 – The Transcatheter Cardiovascular Therapeutics (TCT) 2010 symposium featured a live case broadcast of a physician implanting a new device to treat refractory angina.
At the Antwerp Cardiovascular Institute/ZNA Middelheim in Belgium, Stefan Verheye, M.D., successfully implanted the Neovasc Reducer in the patient’s coronary sinus. Verheye is the principal investigator in the COSIRA study, designed to assess the efficacy of Neovasc’s implantable Reducer device as a treatment for refractory angina.
Refractory angina is a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate blood supply to the heart muscle.
The reducer is implanted in the coronary sinus vein using a minimally invasive percutaneous procedure that is similar to implanting a coronary stent and takes about 20 minutes. It is intended to provide relief by altering blood flow to the coronary sinus, thereby increasing perfusion of oxygenated blood to certain areas of the heart muscle
For more information: www.neovasc.com
More like this
- Patient Enrollment Begins for Trial of Angina Treatment
- Positive Outcomes Shown for Refractory Angina Patient With Neovasc Reducer
- Neovasc Receives CE Mark for Refractory Angina Treatment System
- Neovasc Completes $4.72 Million in Funding for Angina, Mitral Valve Treatments
- Trial Will Examine Stem Cell, Drug Delivery System